Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
Dose Response Curve: Conventional Versus Nonmonotonic01:21

Dose Response Curve: Conventional Versus Nonmonotonic

The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response relationships...
Biological Effects of Radiation02:59

Biological Effects of Radiation

All radioactive nuclides emit high-energy particles or electromagnetic waves. When this radiation encounters living cells, it can cause heating, break chemical bonds, or ionize molecules. The most serious biological damage results when these radioactive emissions fragment or ionize molecules. For example, α and β particles emitted from nuclear decay reactions possess much higher energies than ordinary chemical bond energies. When these particles strike and penetrate matter, they produce ions...
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect01:26

Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect

The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect01:28

Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect

A drug’s dosage and pharmacokinetic properties determine how quickly it acts, how intense its effects are, and how long it lasts. Higher doses increase drug concentration at receptor sites, producing a hyperbolic curve when pharmacologic response is plotted against drug dose. Converting this scale to a log-linear format results in a sigmoidal curve, better representing dose–response relationships.For drugs following a one-compartment model, the pharmacologic response is directly proportional to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is there an association between acute, subacute, and late genitourinary quality of life with prostate SBRT boost?

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Evaluation of mid-treatment <sup>18</sup>F-FDG PET changes in the oral cavity as a predictor of radiation-induced mucositis severity.

Quantitative imaging in medicine and surgery·2026
Same author

Quantitative mid-treatment imaging biomarkers for response prediction after radiotherapy in head and neck cancer: a systematic review and meta-analysis.

EJNMMI research·2026
Same author

Temporal change in liver function after stereotactic body radiation therapy for hepatocellular carcinoma.

Journal of gastrointestinal oncology·2026
Same author

Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study.

The Lancet. Oncology·2026
Same author

Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials.

The Lancet. Oncology·2026

Related Experiment Video

Updated: May 12, 2026

Irradiator Commissioning and Dosimetry for Assessment of LQ &alpha; and &beta; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

Defining a dose-response relationship for prostate external beam radiotherapy.

Yuvnik Trada1, Ash Plank, Jarad Martin

  • 1School of Medicine, University of Queensland, Brisbane, Australia.

Journal of Medical Imaging and Radiation Oncology
|April 5, 2013
PubMed
Summary

Higher radiotherapy doses significantly improve freedom from biochemical failure (FFBF) in low- and intermediate-risk prostate cancer. This study quantifies the dose-response relationship for radiation therapy alone, crucial for optimizing treatment outcomes.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

Related Experiment Videos

Last Updated: May 12, 2026

Irradiator Commissioning and Dosimetry for Assessment of LQ &alpha; and &beta; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

Area of Science:

  • Oncology
  • Radiation Oncology
  • Prostate Cancer Research

Background:

  • Assessing the correlation between radiotherapy dosage and treatment efficacy in prostate cancer is critical.
  • Standardized endpoints and mature follow-up are essential for reliable data in prostate cancer studies.
  • Minimizing confounding factors like hormonal therapy (HT) and metastatic risk enhances the accuracy of radiotherapy outcome analysis.

Purpose of the Study:

  • To quantify the relationship between radiotherapy dose and freedom from biochemical failure (FFBF) in low- and intermediate-risk prostate cancer.
  • To establish dose-response curves for radiotherapy in prostate cancer patients.
  • To analyze outcomes based on radiotherapy dose, differentiating between low- and intermediate-risk disease.

Main Methods:

  • Systematic literature review of studies using radiotherapy alone in conventional fractionation (1.8-2 Gy).
  • Inclusion of studies with a standardized endpoint: Phoenix definition 5-year FFBF.
  • Logistic regression analysis to determine the dose-response relationship for FFBF.

Main Results:

  • Analysis of eight studies comprising 3037 patients (810 low-risk, 2245 intermediate-risk).
  • Strong association found between radiotherapy dose and FFBF in both risk groups treated with radiotherapy alone.
  • For low-risk patients, 52.0 Gy achieved 50% tumor control (TCD50) with 90.3% FFBF at 78 Gy. For intermediate-risk patients, TCD50 was 64.7 Gy with 84.3% FFBF at 78 Gy.

Conclusions:

  • A significant association exists between radiation dose and biochemical outcomes in low- and intermediate-risk prostate cancer.
  • Radiotherapy dose escalation is a key factor in improving FFBF for these patient groups.
  • Standardized reporting in future studies will strengthen the robustness of dose-response analyses in prostate cancer radiotherapy.